{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:37:24Z","timestamp":1778711844729,"version":"3.51.4"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.beha.2017.10.010","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T06:48:20Z","timestamp":1511246900000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel therapies for relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-7011","authenticated-orcid":false,"given":"Puja C.","family":"Arora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.beha.2017.10.010_bib1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.10.010_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/hupa.2002.30221","article-title":"From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades","volume":"33","author":"Swerdlow","year":"2002","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.beha.2017.10.010_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2017.10.010_bib4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2017.10.010_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","author":"Epperla","year":"2017","journal-title":"Br J Haematol"},{"issue":"9873","key":"10.1016\/j.beha.2017.10.010_bib6","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beha.2017.10.010_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2017.10.010_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2017.10.010_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hon.981","article-title":"In\u00a0vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas","volume":"29","author":"Rinaldi","year":"2011","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.beha.2017.10.010_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.beha.2017.10.010_bib11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2017.10.010_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2017.10.010_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10020","key":"10.1016\/j.beha.2017.10.010_bib14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2017.10.010_bib15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2985.2985","article-title":"Multicenter retrospective observational study to assess the clinical characteristics and the outcome of patients with relapsed or refractory mantle cell non-hodgkin's lymphoma treated in Italy according to the ibrutinib named patient program","author":"Stefoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.10.010_bib16","article-title":"Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom","author":"Tucker","year":"2016","journal-title":"Br J Haematol"},{"issue":"Suppl. 15","key":"10.1016\/j.beha.2017.10.010_bib17","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2017.35.15_suppl.7515","article-title":"Updated results of single-agent ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)","volume":"35","author":"Grommes","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.10.010_bib18","author":"Dreger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.10.010_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a real world study","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2017.10.010_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2017.10.010_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3229.3229","article-title":"Major bleeding with ibrutinib: more than expected","author":"Kunk","year":"2016","journal-title":"Blood"},{"issue":"Suppl. 15","key":"10.1016\/j.beha.2017.10.010_bib22","article-title":"Ibrutinib associated infections: a retrospective study","volume":"35","author":"Barbosa","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2017.10.010_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2017.10.010_bib24","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.beha.2017.10.010_bib25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.beha.2017.10.010_bib26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2017.10.010_bib27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for Pi3K inhibition overrides a relapse-specific C481s BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"Suppl. 15","key":"10.1016\/j.beha.2017.10.010_bib28","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.1200\/JCO.2016.34.15_suppl.7570","article-title":"Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial","volume":"34","author":"Lenz","year":"2016","journal-title":"J\u00a0Clin Onocl"},{"issue":"1","key":"10.1016\/j.beha.2017.10.010_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.beha.2017.10.010_bib30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.beha.2017.10.010_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2017.10.010_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A\u00a0phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2017.10.010_bib33","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Col","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.10.010_bib34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2005-07-3041","article-title":"Key role of the p110 isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110 function in B cells","volume":"107","author":"Bilancio","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.10.010_bib35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2017.10.010_bib36","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A\u00a0phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2017.10.010_bib37","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.beha.2017.10.010_bib38","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","author":"Dreyling","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.beha.2017.10.010_bib39","article-title":"The effects of PI3K-\u03b4\/\u03b3 inhibitor, duvelisib, in mantle cell lymphoma in\u00a0vitro and in patient-derived Xenograft studies","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.10.010_bib40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1837.1837","article-title":"Pre-clinical evaluation of the PI3K-p110\u03b2\/\u03b4 inhibitor KA2237 in mantle cell lymphoma","author":"Huang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2017.10.010_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J\u00a0Immunol"},{"issue":"30","key":"10.1016\/j.beha.2017.10.010_bib42","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.10.010_bib43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.10.010_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.13101","article-title":"Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma","volume":"168","author":"Furtado","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2017.10.010_bib45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","article-title":"Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia","volume":"151","author":"Agathocleous","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2017.10.010_bib46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000455939","article-title":"Carfilzomib inhibits constitutive NF-\u03baB activation in mantle cell lymphoma B cells and leads to the induction of apoptosis","volume":"137","author":"Zhang","year":"2017","journal-title":"Acta Haematol"},{"issue":"25","key":"10.1016\/j.beha.2017.10.010_bib47","doi-asserted-by":"crossref","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-\u03baB activity by thalidomide through suppression of I\u03baB kinase activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2017.10.010_bib48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1798.1798","article-title":"MAGNIFY: phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by lenalidomide vs. Rituximab maintenance in subjects with relapsed\/refractory follicular, marginal zone, or mantle cell lymphoma","author":"Andorsky","year":"2016","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.beha.2017.10.010_bib49","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.10.010_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2017.10.010_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1786.1786","article-title":"Effectiveness of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib: the MCL-004 study","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2017.10.010_bib52","doi-asserted-by":"crossref","first-page":"14304","DOI":"10.3390\/molecules190914304","article-title":"Inhibition of the PI3K\/akt\/mTOR signaling pathway in diffuse large B-Cell lymphoma: current knowledge and clinical significance","volume":"19","author":"Majchrzak","year":"2014","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.beha.2017.10.010_bib53","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.10.010_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.10.010_bib55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-015-2570-1","article-title":"Temsirolimus acts as additive with bendamustine in aggressive lymphoma","volume":"95","author":"Zoellner","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2017.10.010_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2977.2977","article-title":"Temsirolimus in combination with bendamustine and rituximab (BeRT) for the treatment of relapsed mantle cell and follicular lymphoma: final phase I\/II results","author":"Hess","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2017.10.010_bib57","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1002\/cncr.29502","article-title":"A\u00a0phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: a Wisconsin Oncology Network study","volume":"121","author":"Fenske","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.beha.2017.10.010_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1359-6101(00)00018-6","article-title":"NF-\u03baB and cell-cycle regulation: the cyclin connection","volume":"12","author":"Joyce","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"issue":"20","key":"10.1016\/j.beha.2017.10.010_bib59","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2017.10.010_bib60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clml.2015.02.021","article-title":"A\u00a0phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"15","author":"Cassaday","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"10.1016\/j.beha.2017.10.010_bib61","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1158\/1078-0432.CCR-11-0955","article-title":"ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high\/mcl-1low profile and synergizes with other antineoplastic agents","volume":"17","author":"Touzeau","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.beha.2017.10.010_bib62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.10.010_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl. 14","key":"10.1016\/j.beha.2017.10.010_bib64","first-page":"LBA2010","article-title":"Chimeric antigen receptor T cells exhibit efficacy in advanced lymphoma","volume":"34","author":"Kochenderfer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2017.10.010_bib65","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2017.10.010_bib66","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/leu.2013.249","article-title":"Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma","volume":"28","author":"Axelrod","year":"2014","journal-title":"Leukemia"},{"issue":"Suppl. 15","key":"10.1016\/j.beha.2017.10.010_bib67","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2017.35.15_suppl.7520","article-title":"Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): primary endpoint assessment of the phase 2 AIM study","volume":"35","author":"Tam","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.10.010_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2958.2958","article-title":"Initial report of a multi-institution phase I\/Ib study of ibrutinib with venetoclax in relapsed or refractory mantle cell lymphoma","author":"Portell","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.10.010_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1096.1096","article-title":"Lymphoid-like environment, which promotes proliferation and induces resistance to BH3-mimetics, is counteracted by obinutuzumab in MCL: Biological rationale for the oasis clinical trial","author":"Chiron","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.10.010_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.148.148","article-title":"Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: first results from the nordic lymphoma group MCL6 (PHILEMON) phase II trial","author":"Jerkeman","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2017.10.010_bib71","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.10.010_bib72","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.150.150","article-title":"A\u00a0phase I trial of ibrutinib plus palbociclib in patients with previously treated mantle cell lymphoma","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"Suppl. 15","key":"10.1016\/j.beha.2017.10.010_bib73","first-page":"754","article-title":"Phase I dose escalation of ibrutinib and buparlisib in relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)","volume":"35","author":"Batlevi","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.10.010_bib74","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.641.641","article-title":"TGR-1202 in combination with ibrutinib in patients with relapsed or refractory CLL or MCL: preliminary results of a multicenter phase I\/Ib study","author":"Davids","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.10.010_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2963.2963","article-title":"Results of a phase 2 trial evaluating efficacy and safety of entospletinib (GS-9973) in patients with mantle cell lymphoma","author":"Sharman","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2017.10.010_bib76","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"issue":"Suppl. 15","key":"10.1016\/j.beha.2017.10.010_bib77","first-page":"7523","article-title":"Participation in clinical trials to improve outcomes of patients with relapsed lymphoma","volume":"35","author":"Nowakowski","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.10.010_bib78","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1112.1112","article-title":"Mantle cell lymphoma management and outcome in the U.K's population-based haematological malignancy research network","author":"Patmore","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2017.10.010_bib79","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1840.1840","article-title":"Inhibiting SOX11-DNA interaction in mantle cell lymphoma","volume":"128","author":"Christie","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2017.10.010_bib80","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1846.1846","article-title":"Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on DLL4 and is a potential target for specific antibody therapy","volume":"128","author":"H\u00f6ring","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2017.10.010_bib81","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.beha.2017.10.010_bib82","first-page":"1132","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin\u2019s lymphoma","volume":"130","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2017.10.010_bib83","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","article-title":"HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma","volume":"128","author":"Jacobson","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2017.10.010_bib84","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.10.010_bib85","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.exphem.2017.01.001","article-title":"Androgen receptor expression in mantle cell lymphoma: potential novel therapeutic implications","volume":"49","author":"Mostaghel","year":"2017","journal-title":"Exp Hematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T05:46:11Z","timestamp":1603345571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1521692617300713"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.010","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies for relapsed\/refractory mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}